Currently Viewing:
Newsroom
Currently Reading
Unmet Care Targets Suggest Need for Improved Diabetes Care Accessibility
August 18, 2019 – Alison Rodriguez
Blood Clots in MPN Related to Higher Cost, Length of Stay for Patients With MPN
August 17, 2019 – AJMC Staff
Researchers Seek to Determine Genetic Variability in Parkinson Progression
August 17, 2019 – AJMC Staff
FDA Panel Backs Use of Descovy for HIV Prevention in Men, Transgender Women
August 16, 2019 – Jaime Rosenberg
Researcher Excited About Future of Psoriasis Treatment
August 16, 2019 – Allison Inserro
This Week in Managed Care: August 16, 2019
August 16, 2019
AJMC® in the Press, August 16, 2019
August 16, 2019 – AJMC Staff
Pediatric Leukemia Treatment Linked to Increased Risk of Infections, Study Finds
August 16, 2019 – Alison Rodriguez
5 Findings From the August 2019 Issue of AJMC®
August 16, 2019 – Christina Mattina

Amgen, Novartis Announce Positive Results of Erenumab Trial for Episodic Migraine

Jaime Rosenberg
Amgen and Novartis announced full results from the LIBERTY trial, which assessed erenumab as preventive treatment for patients with episodic migraine who had previously failed on 2 to 4 treatments. The study met its primary endpoint and all of its secondary endpoints.
Amgen and Novartis announced full results from the Phase 3b LIBERTY trial, which assessed erenumab (Aimovig) as preventive treatment for patients with episodic migraine who had previously failed on other treatments.

Erenumab is the only fully human monoclonal antibody under regulatory review for the selective blocking of the calcitonin gene-related peptide (CGRP) receptor, and LIBERTY is the first study to investigate a treatment targeting the CGRP pathway in this patient population, according to a release from Amgen.

“We are encouraged by these new findings, which add to the growing body of clinical evidence supporting potential use of Aimovig across a broad spectrum of patients with migraine, all of whom live with what is considered one of the most disabling diseases,” said Sean E Harper, MD, executive vice president, research and development, Amgen, in a statement.

The study included 246 patients who had previously been treated with 2 to 4 treatments. Participants were randomized 1:1 to receive monthly subcutaneous injections of either 140 mg of erenumab or placebo for 12 weeks. The primary endpoint was the proportion of patients experiencing a 50% or greater reduction in mean monthly migraine days during weeks 9 through 12.

At baseline, the proportion of patients who failed 2, 3, and 4 previous treatments were 38.6%, 37.8%, and 22.8%, respectively. Results showed that those taking erenumab had nearly three-fold higher odds of having their migraine days reduced by at least 50% (30.3% versus 13.7%). Safety and tolerability was comparable to placebo, and no patients in the erenumab cohort discontinued due to adverse events.

The erenumab cohort also had statistically significant improvements from baseline compared to placebo across all secondary endpoints, including:
  • Reduction in monthly migraine days
  • Decrease in acute migraine-specific drug use
  • 75% or greater reduction in monthly migraine days
  • 100% reduction in monthly migraine days
  • Improved physical functioning and ability to complete everyday activities as measured by the Migraine Physical Function Impact Diary scales
“The LIBERTY study distinctively demonstrates the ability of an anti-CGRP receptor antibody to significantly reduce migraine frequency and its associated burden in patients who could not find the relief they need with the currently available preventive treatment options,” said Uwe Reuter, MD, managing medical director, Charité Universitätsmedizin, and a co-author of the study, in a press release from Novartis. “These compelling new data offer new hope of fewer migraine days to those people with migraine who may have cycled through current standard of care unsuccessfully for years due to lack of efficacy and tolerability.”

The data will be presented next week at the 70th Annual Meeting of the American Academy of Neurology in Los Angeles, California.

Related Articles

Migraine in Managed Care
Cost of Migraine Management: A Pharmacoeconomic Overview
Emerging Therapies and Preventive Treatments for Migraine
Novartis Says CGRP Migraine Blocker Shows Good Results in Late-Stage Study
ICER Study Compares Cost-Effectiveness of CGRP Inhibitors for Migraine
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up